Trials / Completed
CompletedNCT05606094
Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
A Multinational, Multicenter, Non-Interventional, Retrospective, Observational, Real-World Study: Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in East Asia (HER2+ GASTA Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to understand real-world treatment patterns, participant characteristics (demographic and clinico-pathological characteristics), clinical outcomes and safety of different treatment regimens, and healthcare resource utilization in East Asia for HER2-positive locally advanced or metastatic gastric or gastroesophageal adenocarcinoma (de novo advanced disease, relapsed/progressed) in a real-world setting.
Conditions
Timeline
- Start date
- 2023-03-09
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
- First posted
- 2022-11-04
- Last updated
- 2023-12-15
Locations
31 sites across 4 countries: China, Hong Kong, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT05606094. Inclusion in this directory is not an endorsement.